FDA aims to speed biosimilar approvals to increase competition, but experts warn drug prices may not drop quickly.
Lowering the prices of prescription drugs has been high on United States President Donald Trump’s agenda since he took office in January. He has taken a number of steps, including striking deals with pharmaceutical companies, to lower the costs of prescription drugs.
Trump has also directed the Food and Drug Administration (FDA) to streamline its regulation process to boost cheaper copycat drugs, such as generic and biosimilar drugs.
Biosimilars are highly similar versions of biologics, a group of drugs produced through biological processes. One of the most widely used biologic drugs is insulin, which is used to treat diabetes.
Biologics, which make up just 5 percent of prescriptions, account for more than half of the total expenditures on medicines in the US, according to the health data analysis company IQVIA.
The Trump administration said it hopes to make these medications more affordable, partly by increasing access to biosimilars.
So what are biologics and biosimilars, and will the administration’s proposals help drive down their costs?
What are biologics?
Biologics is short for biological medicat
Continue Reading on Al Jazeera
This preview shows approximately 15% of the article. Read the full story on the publisher's website to support quality journalism.